Emerging drugs for focal epilepsy

References

• de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008;12:540–546.
   PubMed Web of Science ®Google Scholar
• MacDonald BK, Cockerell OC, Sander JW, et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain. 2000;123(Pt 4):665–676.
   PubMed Web of Science ®Google Scholar
• Ngugi AK, Kariuki SM, Bottomley C, et al. Incidence of epilepsy: a systematic review and meta-analysis. Neurol. 2011;77:1005–1012.
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Beghi E, Forsgren L, et al. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia. 2007;48:2224–2233.
   PubMed Web of Science ®Google Scholar
• Covanis A, Guekht A, Li S, et al. From global campaign to global commitment: the world health assembly’s resolution on epilepsy. Epilepsia. 2015;56:1651–1657.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurol. 2012;78:1548–1554.
   PubMed Web of Science ®Google Scholar
• French JA, White HS, Klitgaard H, et al. Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia. 2013;54(Suppl 4):3–12.
   PubMedGoogle Scholar
• Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069–1077.
   PubMed Web of Science ®Google Scholar
• Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia. 2010;51:7–26.
   PubMed Web of Science ®Google Scholar
• Mula M. Third generation antiepileptic drug monotherapies in adults with epilepsy. Expert Rev Neurother. 2016;16:1087–1092.
   PubMed Web of Science ®Google Scholar
• Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10:446–456.
   PubMed Web of Science ®Google Scholar
• Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res. 2017;7:61–76.
   PubMedGoogle Scholar
• O’Shaughnessy WB. On the preparations of the Indian hemp, or Gunjah. Prov Med J Retrosp Med Sci. 1843;5:363–369.
   Google Scholar
• Gowers WR. 1881. William R. Epilepsy and other chronic convulsive diseases : their causes, symptoms, & treatment [internet]. London: Churchill. Available from: http://archive.org/details/epilepsyotherchr00goweuoft
   Google Scholar
• Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64:21–47.
   PubMed Web of Science ®Google Scholar
• Baulieu EE, Robel P. Neurosteroids: a new brain function? J Steroid Biochem Mol Biol. 1990;37:395–403.
   PubMed Web of Science ®Google Scholar
• Compagnone NA, Mellon SH. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front Neuroendocrinol. 2000;21:1–56.
   PubMed Web of Science ®Google Scholar
• Jacob TC, Moss SJ, Jurd R. GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat Rev Neurosci. 2008;9:331–343.
   PubMed Web of Science ®Google Scholar
• Zorumski CF, Paul SM, Izumi Y, et al. Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev. 2013;37:109–122.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the thirteenth eilat conference on new antiepileptic drugs and devices (EILAT XIII). Epilepsia. 2017;58:181–221.
   PubMed Web of Science ®Google Scholar
• Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics. 2009;6:392–401.
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21–35.
   PubMed Web of Science ®Google Scholar
• Citraro R, Leo A, Constanti A, et al. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol Res. 2016;107:333–343.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293.
   PubMed Web of Science ®Google Scholar
• Masino SA, Kawamura M, Ruskin DN. Adenosine receptors and epilepsy: current evidence and future potential. Int Rev Neurobiol. 2014;119:233–255.
   PubMed Web of Science ®Google Scholar
• Łuszczki JJ, Kozicka M, Swiader MJ, et al. 2-Chloro-N6-cyclopentyladenosine enhances the anticonvulsant action of carbamazepine in the mouse maximal electroshock-induced seizure model. Pharmacol Rep. 2005;57:787–794.
   PubMed Web of Science ®Google Scholar
• Zuchora B, Wielosz M, Urbańska EM. Adenosine A1 receptors and the anticonvulsant potential of drugs effective in the model of 3-nitropropionic acid-induced seizures in mice. Eur Neuropsychopharmacol. 2005;15:85–93.
   PubMed Web of Science ®Google Scholar
• Kumar V, Sharma A. Adenosine: an endogenous modulator of innate immune system with therapeutic potential. Eur J Pharmacol. 2009;616:7–15.
   PubMed Web of Science ®Google Scholar
• Aronica E, Bauer S, Bozzi Y, et al. Neuroinflammatory targets and treatments for epilepsy validated in experimental models. Epilepsia. 2017;58(Suppl 3):27–38.
   PubMedGoogle Scholar
• Boison D. Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev. 2013;65:906–943.
   PubMed Web of Science ®Google Scholar
• Lang R, Gundlach AL, Holmes FE, et al. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol Rev. 2015;67:118–175.
   PubMed Web of Science ®Google Scholar
• Mazarati AM, Liu H, Soomets U, et al. Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J Neurosci. 1998;18:10070–10077.
   PubMed Web of Science ®Google Scholar
• Lerner JT, Sankar R, Mazarati AM. Galanin and epilepsy. EXS. 2010;102:183–194.
   PubMedGoogle Scholar
• Kokaia M, Holmberg K, Nanobashvili A, et al. Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. Proc Natl Acad Sci USA. 2001;98:14006–14011.
   PubMed Web of Science ®Google Scholar
• Ec C. Potassium channels (including KCNQ) and epilepsy. In: Jl N, Avoli M, Ma R, et al., editors. Jasper’s basic mechanisms of the epilepsies [internet]. 4th ed. Bethesda (MD): National Center for Biotechnology Information (US); 2012. Available from: http://www.ncbi.nlm.nih.gov/books/NBK98164/
   Google Scholar
• Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet. 1998;18:25–29.
   PubMed Web of Science ®Google Scholar
• Barrese V, Miceli F, Soldovieri MV, et al. Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clin Pharmacol. 2010;2:225–236.
   PubMedGoogle Scholar
• Boscia F, Annunziato L, Taglialatela M. Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharmacol. 2006;51:283–294.
   PubMed Web of Science ®Google Scholar
• Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics. 2007;4:149–154.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015;111:85–141.
   PubMed Web of Science ®Google Scholar
• Ibeas Bih C, Chen T, Nunn AVW, et al. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12:699–730.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Orlando P, Moriello AS, et al. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiologica. 2012;204:255–266.
   PubMed Web of Science ®Google Scholar
• Ružić Zečević D, Folić M, Tantoush Z, et al. Investigational cannabinoids in seizure disorders, what have we learned thus far? Expert Opin Investig Drugs. 2018;27:535–541.
   PubMed Web of Science ®Google Scholar
• Hill AJ, Mercier MS, Hill TDM, et al. Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol. 2012;167:1629–1642.
   PubMed Web of Science ®Google Scholar
• GW Pharmaceuticals. GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006 [Internet]. [ cited 2018 Aug 30]. Available from: http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-announces-preliminary-results-phase-2a-study
   Google Scholar
• French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388:2153–2163.
   PubMed Web of Science ®Google Scholar
• Wiesner JB, Ugarkar BG, Castellino AJ, et al. Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. J Pharmacol Exp Ther. 1999;289:1669–1677.
   PubMed Web of Science ®Google Scholar
• Metcalf CS, Klein BD, McDougle DR, et al. Preclinical evaluation of intravenous NAX 810-2, a novel GalR2-preferring analog, for anticonvulsant efficacy and pharmacokinetics. Epilepsia. 2017;58:239–246.
   PubMed Web of Science ®Google Scholar
• Wang N, Mi X, Gao B, et al. Minocycline inhibits brain inflammation and attenuates spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurosci. 2015;287:144–156.
   PubMed Web of Science ®Google Scholar
• Wang DD, Englot DJ, Garcia PA, et al. Minocycline- and tetracycline-class antibiotics are protective against partial seizures in vivo. Epilepsy Behav. 2012;24:314–318.
   PubMed Web of Science ®Google Scholar
• Beheshti Nasr SM, Moghimi A, Mohammad-Zadeh M, et al. The effect of minocycline on seizures induced by amygdala kindling in rats. Seizure. 2013;22:670–674.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Schmidt D. Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development. Pharmacol Res. 2016;104:38–48.
   PubMed Web of Science ®Google Scholar
• Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792–802.
   PubMed Web of Science ®Google Scholar
• Mula M, Cock HR. More than seizures: improving the lives of people with refractory epilepsy. Eur J Neurol. 2015;22:24–30.
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs. 2009;23:121–137.
   PubMed Web of Science ®Google Scholar
• Mula M. Epilepsy and psychiatric comorbidities: drug selection. Curr Treat Options Neurol. 2017;19:44.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Ambrosi M, Pavone P, et al. Pediatric status epilepticus: improved management with new drug therapies? Expert Opin Pharmacother. 2017;18:789–798.
   PubMed Web of Science ®Google Scholar